Altimmune SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 12, 2026, 7:33 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedAltimmune Reports Q3 2026 Net Loss of $0.15 Per Share, a $0.01 Miss Versus $0.14 Consensus, as R&D Spending Rises
8-KOct. 29, 2026, 7:03 a.m. ETView on SEC.gov
Creation of a direct financial obligation
AI summary, unreviewedAltimmune draws $10.0 million Tranche Three under $125.0 million Hercules loan after clinical and financial milestones
8-KOct. 27, 2026, 8:16 a.m. ETView on SEC.gov
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedAltimmune Adds Two Biotech Veterans Greenleaf and Howarth to Board as Three Directors Retire
8-KSept. 29, 2026, 7:03 a.m. ETView on SEC.gov
Departure/appointment of directors or officers
8-KAug. 12, 2026, 7:33 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
8-KJuly 28, 2026, 7:04 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits